Fig. 3From: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyTime to response, duration of response, and time on therapy (weeks) in arm N + P. Patients with confirmed response are presented (n = 9, no ongoing responses were observed)Back to article page